Atopic dermatitis - Contemporary view on pathomechanism and management. Position statement of the Polish Dermatological Society specialists;Atopowe zapalenie skóry - Współczesne pogla̧dy na patomechanizm oraz metody postȩpowania diagnostyczno-leczniczego. Stanowisko grupy specjalistów Polskiego Towarzystwa Dermatologicznego

Postepy Dermatologii i Alergologii

Volumn 27, Issue 5, 2010, Pages 365-383

  Silny, Wojciech ^a   Czarnecka Operacz, Magdalena ^a   Gliñski, Wiesław ^b   Samochocki, Zbigniew ^b   Jenerowicz, Dorota ^a  

^a Katedra i Klinika Dermatologii   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Aetiopathogenesis; Atopic dermatitis; Clinical picture; Management

Indexed keywords

ALLERGEN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AUTOANTIGEN; CALCINEURIN INHIBITOR; CYTOKINE; EMOLLIENT AGENT; FOOD ALLERGEN; GLUCOCORTICOID; IMMUNOGLOBULIN E ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; CREAM; DENDRITIC CELL; DISEASE CONTROL; DISEASE SEVERITY; ECZEMA; EOSINOPHIL; GENETIC ASSOCIATION; HUMAN; IMMUNE DYSREGULATION; IMMUNOHISTOLOGY; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INNATE IMMUNITY; LICHENOID; LOTION; OINTMENT; PATHOPHYSIOLOGY; PRIMARY PREVENTION; REGULATORY T LYMPHOCYTE; REVIEW; SECONDARY PREVENTION; SKIN CARE; T LYMPHOCYTE; TH17 CELL;

EID: 78649725886     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Werfel T, Kapp A. Environmental and other major provocation factors in atopic dermatitis. Allergy 1998; 53: 731-9. (Pubitemid 28374753)
2. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118: 152-69
3. and Allergy 2006; 61: 969-87.
4. Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr 2007; 54: 241-73.
5. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-94.
6. Werfel T. The role of leukocytes, keratinocytes and allergen-specific IgE. J Invest Dermatol 2009; 129: 1878-91.
7. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
8. Brown SJ, McLean WHI. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol 2009; 129: 543-52.
9. O'Regan GM, Irvine AD. The role of filaggrin loss-of-function mutations in atopic dermatitis. Curr Opin Allergy Clin Immunol 2008; 8: 406-10.
10. Leung DY, Bhan AK, Schneeberger EE, et al. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies J Allergy Clin Immunol 1983; 71: 47-56.
11. Zachary CB, Allen MH, MacDonald DM. In situ quantification of T-lymphocyte subsets and Langerhans cells in the inflammatory infiltrate of atopic eczema. Br J Dermatol 1985; 112: 149-56.
12. Picker LJ, Michie SA, Rott LS, et al.. A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T-cells at cutaneous sites. Am J Pathol 1990; 136: 1053-68.
13. Santamaria Babi LF, Picker LJ, Perez Soler MT, et al. Circulating allergen-reactive T-cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med 1995; 181: 1935-40.
14. Van Reijsen FC, Bruijnzeel-Koomen CA, Kalthoff FS, et al. Skin-derived aeroallergen-specific T-cell clones of Th-2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 90: 184-93.
15. Bieber T. The pro- and anti-inflammatory properties of human antigen-presenting cells expressing the high affinity receptor for IgE (Fc epsilon Rl). Immunobiology 2007; 212: 499-503. (Pubitemid 46830354)
16. Novak N, Peng W, Yu C. Network of myeloid and plasmacytoid dendritic cells in atopic dermatitis. Adv Exp Med Biol 2007; 601: 97-104.
17. Homey B, Steinhoff M, Ruzicka T, et al. Cytokines and chemokines orchestrate atopic skin inflammation. J AllergyClin Immunol 2006; 118: 178-89. (Pubitemid 43946487)
18. Steinhoff M, Steinhoff A, Homey B, et al. Role of vasculature in atopic dermatitis. J Allergy Clin Immunol 2006; 118: 190-7.
19. Reich K, Hugo S, Middel P, Blaschke V, et al. Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis. Allergy Clin Immunol 2002; 109: 681-7.
20. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin lnvest 1994; 94: 870-6. (Pubitemid 24251022)
21. Toda M, Leung DY, Molet S, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 111: 875-81. (Pubitemid 36470263)
22. Wu K, Higashi N, Hansen ER, et al. Telomerase activity is increased and telomere length shortened in T-cells from blood of patients with atopic dermatitis and psoriasis. J Immunol 2000; 165: 4742-7.
23. Schmid-Ott G, Jaeger B, Adamek C, et al. Levels of circulating CD8 (+) T-lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 171-7. (Pubitemid 32105262)
24. Akdis M, Simon HU, Weigl L. Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T-cells respond to superantigen contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 1999; 163: 466-75. (Pubitemid 29295875)
25. Seneviratne SL, Jones L, King AS, et al. Allergen-specific CD8(+) T cells and atopic disease. J Clin Invest 2002; 110: 1283-91. (Pubitemid 35285754)
26. Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006; 118: 930-7.
27. Wittmann M, Alter M, Stunkel T, et al. Cell-to-cell contact between acti-vated CD4+ T-lymphocytes and unprimed monocytes interferes with a TH-1 response. J Allergy Clin Immunol 2004; 114: 965-73.
28. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-31.
29. Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908-15.
30. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007; 27: 98-114.
31. Bilsborough J, Leung DY, Maurer M, et al. IL-31 is 2, associated with cutaneous lymphocyte antigen-positive skin homing T-cells in patients with atopic dermatitis. Allergy Clin Immunol 2006; 117: 418-25.
32. Takaoka A, Arai l, Sugimoto M, et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 2006; 15: 161-7.
33. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T-cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-7.
34. Gutzmer R, Mommert S, Gschwandtner M, et al. The histaminȩ H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol 2009; 123: 619-25.
35. Van Beelen AJ, Teunissen MB, Kapsenberg ML, et al. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 2007; 7: 374-81.
36. Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008; 128: 2625-30.
37. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116: 961-8.
38. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T-cells. J Allergy Clin Immunol 2007; 120: 744-50.
39. Cardona ID, Goleva E, Ou LS, et al. Staphylococcal enterotoxin B inhibits regulatory T-cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes. J Allergy Clin Immunol 2006; 117: 688-95.
40. Verhagen J, Akdis M, Traidl-Hoffmann C, et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006; 117: 176-83.
41. Franz B, Fritzsching B, Riehl A et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007; 56: 1910-20.
42. Schnopp C, Rad R, Weidinger A, et al. Fox-P3-positive regulatory T-cells are present in the skin of generalized atopic eczema patients and arȩ not particularly affected by medium-dose UVA1 therapy. Photodermatol Photoimmunol Photomed 2007; 23: 81-5.
43. Novak N, Valenta R, Bohle B, et al. Fc epsilon Rl engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immunol 2004; 113: 949-57.
44. Maintz L, Novak N. Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol 2007; 17: 267-83.
45. Wollenberg A, Wagner M, Cunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-102. (Pubitemid 35434173)
46. Wittmann M, Werfel T. Interaction of keratinocytes with infiltrating lymphocytes in allergic eczematous skin diseases. Curr Opin Allergy Clin Immunol 2006; 6: 329-34. (Pubitemid 44368238)
47. Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 2007; 28: 248-51.
48. McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol 2006; 118: 202-8.
49. De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 2009; 129: 14-30.
50. Soumelis V, Liu YJ. Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. Springer Semin Immunopathol 2004; 25: 325-33.
51. Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005; 202: 1213-23.
52. Albanesi C, Scarponi C, Sebastiani S, et al. A cytokine-to-chemokine axis between T-lymphocytes and keratinocytes can favor Th-1 cell accumulation in chronic inflammatory skin diseases. J Leukoc Biol 2001, 70: 617-23.
53. Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T-cells: possible role in atopic dermatitis. J Invest Dermatol 2006; 126: 1043-51.
54. Han GW, Iwatsuki K, Inoue M, et al. lnterleukin-15 is not a constitutive cytokine in the epidermis, but is inducible in culture or inflammatory conditions. Acta Derm Venereol 1999; 79: 37-40. (Pubitemid 29079326)
55. Giustizieri ML, Albanesi C, Fluhr J, et al. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004; 114: 1176-82. (Pubitemid 39469162)
56. Trautmann A, Akdis M, Kleemann D, et al. T-cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000; 106: 25-35. (Pubitemid 30437237)
57. Shimizu M, Matsuda A, Yanagisawa K, et al. Functional SNPs in the distal promoter of the ST2 gene arȩ associated with atopic dermatitis. Hum Mol Genet 2005; 14: 2919-27.
58. Leiferman KM, Ackerman SJ, Sampson HA, et al. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med 1985; 313: 282-5.
59. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004; 59: 561-70.
60. Wedi B, Raap U, Kapp A. Significant delay of apoptosis and Fas resistance in eosinophils of subjects with intrinsic and extrinsic type of atopic dermatitis. Int Arch Allergy Immunol 1999; 118: 234-5.
61. Schmid-Ott G, Jaeger B, Meyer S, et al. Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls. J Allergy Clin Immunol 2001; 108: 455-62. (Pubitemid 32881070)
62. Elsner J, Kapp A. Regulation and modulation of eosinophil effector functions. Allergy1999; 54: 15-26.
63. Raap U, Werfel T, Goltz C, et al. Circulating levels of brain-derived neurotrophic factor correlate with disease severity in the intrinsic type of atopic dermatitis. Allergy 2006; 61: 1416-8. (Pubitemid 44665305)
64. Breuer K, Haeussler S, Kapp A, et al. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002; 147: 55-61. (Pubitemid 34779438)
65. Howell MD, Wollenberg A, Gallo RL, et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-41.
66. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-60.
67. Nomura l, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171: 3262-9.
68. Hasannejad H, Takahashi R, Kimishima M. Selective impairment of Toll-like receptor 2-mediated proinflammatory cytokine production by monocytes from patients with atopic dermatitis. J Allergy Clin Immunol 2007; 120: 69-75.
69. Niebuhr M, Lutat C, Sigel S, Werfel T. Impaired TLR-2 expression and TLR-2 mediated cytokine secretion in macrophages from patients with atopic dermatitis. Allergy 2009; 63: 728-34.
70. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004; 113: 565-7.
71. Niebuhr M, Langnickel J, Draing C. Dysregulation of toll-like receptor-2 (TLR-2)-induced effects in monocytes from patients with atopic dermatitis: impact of the TLR-2 R753Q polymorphism. Allergy 2008; 63: 728-34. (Pubitemid 351591862)
72. Mrabet-Dahbi S, Dalpke A, Frey M, et al. The toll-like receptor 2 (TRL-2) R753Q mutation modifies cytokine production and TLR expression in atopic dermatitis. J Allergy Clin Immunol 2008; 121: 1013-9.
73. Scheynius A, Johansson C, Buentke E. Atopic eczema/dermatitis syndrome and Malassezia. Int Arch Allergy Immunol 2002; 127: 161-9.
74. Selander C, Zargari A, Mollby R, et al. Higher pH level, corresponding to that on the skin of patients with atopic eczema, stimulates the release of Malassezia sympodialis allergens. Allergy 2006; 61: 1002-8.
75. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-7.
76. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol 2006; 118: 209-13.
77. Novembre E, Cianferoni A, Lombard E. Natural history of "intrinsic" atopic dermatitis. Allergy 2001; 56: 452-3.
78. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses differential expression of H1 and H2 receptors. Nature 2001; 413: 420-5. (Pubitemid 32928596)
79. Gytzmer R, Diestel C, Mommert S, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 2005; 174: 5224-32. (Pubitemid 40593160)
80. Dijkstra D, Leurs R, Chazot P, et al. Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. J Allergy Clin Immunol 2007; 120: 300-7.
81. Werfel T, Breuer K. Role of food allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol 2004; 4: 379-85. (Pubitemid 39274079)
82. Reekers R, Beyer K, Niggemann B, et al. The role of circulating food antigen-specific lymphocytes in food allergic children with atopic dermatitis. Br J Dermatol 1996; 135: 935-41.
83. Werfel T, Hentschel M, Kapp A, et al. Dichotomy of blood- and skin-derived IL-4-producing allergen-specific T-cells and restricted V beta repertoire in nickel-mediated contact dermatitis. J Immunol 1997; 158: 2500-5.
84. Van Reijsen FC, Felius A, Wauters EA, et al. T-cell reactivity for a peanut-derived epitope in the skin of a young infant with atopic dermatitis. J Allergy Clin Immunol 1998; 101: 207-9. (Pubitemid 28152382)
85. Bohle B, Zwolfer B, Heratizadeh A, et al. Cooking birch pollen-related food: divergent consequences for IgE- and T-cell-mediated reac-tivity in vitro and in vivo. J Allergy Clin Immunol 2006; 118: 242-9. (Pubitemid 43946469)
86. Darsow U, Laifaoui J, Kerschenlohr K, et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004; 59: 1318-25.
87. Turjanmaa K, Darsow U, Niggemann B, et al. EAACI/GA2LEN position paper: present status of the atopy patch test. Allergy 2006; 61: 1377-34.
88. Sager N, Feldmann A, Schilling G, et al. House dust mite-specific T-cells in the skin of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992; 89: 801-10.
89. Werfel T, Morita A, Grewe M, et al Allergen specificity of skin-infiltrating T-cells is not restricted to type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 1996; 107: 871-6.
90. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347: 15-8. (Pubitemid 26012411)
91. Holm L, Bengtsson A, Hage-Hamsten M, et al. Effectiveness of occlusive bedding in the treatment of atopic dermatitis a placebo-controlled trial of 12 months' duration. Allergy 2001; 56: 152-8.
92. Oosting AJ, Bruin-Weller MS, Terreehorst I, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. J Allergy Clin Immunol 2002; 110: 500-6.
93. Bussmann C, Bockenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006; 118: 1292-8.
94. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006; 61: 202-5.
95. Czarnecka-Operacz M, Silny W. Specific Immunotherapy in atopic dermatitis. Acta Dermatovenerol Croat 2006; 1: 52-9.
96. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis. Results of a double-blind, placebo-controlled study. Allergologie 2006; 5: 171-83.
97. Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37: 1277-85. (Pubitemid 47372291)
98. Bunikowski R, Mielke M, Skarabis H, et al. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol 1999; 103: 119-24. (Pubitemid 29063201)
99. Breuer K, Wittmann M, Bosche B. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy 2000; 55: 551-5.
100. Scalabrin DM, Bavbek S, Perzanowski MS. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 1999; 104: 1273-9.
101. Schmid-Grendelmeier P, Scheynius A, Crameri R. The role of sensitization to Malassezia sympodialis in atopic eczema. Chem Immunol Allergy 2006; 91: 98-109. (Pubitemid 43097199)
102. Valenta R, Mittermann I, Werfel T, et al. Linking allergy to autoimmune disease. Trends Immunol 2009; 30: 109-16.
103. Heratizadeh et. al. - oddane do druku
104. Mothes N, Niggemann B, Jenneck C, et al. The cradle of IgE autoreactivity in atopic eczema lies in early infancy. J Allergy Clin Immunol 2005; 116: 706-9.
105. Schmid-Grendelmeier P, Fluckiger S, Disch R, et al. IgE-mediated and T-cell-mediated autoimmunity against manganese superox-ide dismutase in atopic dermatitis. J AllergyClin Immunol 2005; 115: 1068-75. (Pubitemid 40616225)
106. Sugiura K, Muro Y, Nishizawa Y, et al. LEDGF/ DFS70, a major autoantigen of atopic dermatitis, is a component of keratohyalin granules. J Invest Dermatol 2007; 127: 75-80. (Pubitemid 46005663)
107. Elias PM, Wood LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermatol 1999; 10: 119-26.
108. Taieb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis 1999; 41: 177-80.
109. Novak N, Allam JP, Bieber T. Allergic hyperreactivity to microbial components - a trigger factor of "intrinsic" atopic dermatitis? J Allergy Clin Immunol 2003; 112: 215-6.
110. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention J Allergy Clin Immunol 2000; 105: 860-76.
111. Cork M, Robinson D, VasilopoulosY, Ferguson A. The effects of topical corticosteroids and pimecrolimus on skin barrier function, gene expression and topical drug penetration in atopic eczema and unaffected controls. J Am Acad Dermatol 2007, 56 (Suppl. 2): AB69.
112. Bartoszak L, Czarnecka-Operacz M. Alergia kontaktowa u dzieci chorych na atopowe zapalenie skóry. Post Dermatol Alergol 2007; 24: 120-6. (Pubitemid 47073883)
113. Vieluf D, Kunz B, Bieler T, et al. "Atopy patch test" witch aeroallergens in patients with atopic eczema. Allegro J 1993; 2: 9-12.
114. Hanifin JM, Rajka G. Diagnostic features of atopic egzema. Acta Dermatol Venerol 1980; 92: 44-7.
115. Johnie H, Vach W, Norbert LA, et al. A compromision between criteria for diagnosting atopic eczema in infants. Br J Dermatol 2005; 153: 352-58. (Pubitemid 41228433)
116. Tagami H. Japanes Dermatological Association Criteria for the diagnosis of atopic dermatitis. J Dermatol 1995; 22: 966-67.
117. Schmitt J, Langan S, Williams AC. What are the best autcome mesurements for atopic egzema? Asysteniatic rewiew. J Allergy Clin Immunol 2007; 120: 1389-98.
118. Silny W, Czarnecka-Operacz M, Silny P. The news scoring system for evalution of skin inflamation. Acta Dermatovenerol Croat 2005; 13: 219-24.
119. Gliñski W, Kruszewski J, Silny W, et al. Postȩpowanie diagnostyczno-profilaktyczno-lecznicze w atopowym zapaleniu skóry. Pol Merk Lek 2004; 17 (Supl. 3): 3-15.
120. Darsow W, Wollenberg A, Simon D et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. JEADV 2009.
121. Anderson PC, Dinulos JG. Are the new moisturizers more effective? Curr Opin Ped 2009; 21: 486-90.
122. Oranje AP, Devillers ACA, Kunz B, et al. Treatment of patients with atopic dermatitis with diluted steroids and/or emollients. An expert panel's opinion and review of the literature. JEADV 2006; 20: 1277-86.
123. Loden M. The skin barrier and use of moisturizers in atopic dermatitis. Clin Dermatol 2003; 21: 145-57.
124. Czarnecka-Operacz M. Sucha skóra jako aktualny problem kliniczny. Post Dermatol Alergol 2006; 2: 49-56.
125. Cork MJ, Danby S. Skin barrier breakdown: a renaissance in emollient therapy. Br J Nurs 2009; 18: 872, 874, 876-77.
126. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003; 149: 582-9.
127. Jenerowicz D, Czarnecka-Operacz M, Silny W. Problem fobii kortykosteroidowej u chorych na atopowe zapalenie skóry. Wiad Lek 2005; 11-12: 607-15.
128. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003; 21: 193-200. (Pubitemid 36629331)
129. Bewley A; Dermatology Working Group. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol 2008; 158: 917-20.
130. Czarnecka-Operacz M, Silny W. Nowe leki w miejscowej terapii atopowego zapalenia skóry. Pol Merk Lek 2003; 14: 682-84. (Pubitemid 36875024)
131. Silny W, Czarnecka-Operacz M. Skuteczność i bezpieczeñstwo miejscowych inhibitorów kalcyneuryny w leczeniu atopowego zapalenia skóry. Przegl Dermatol 2009; 96: 99-103.
132. Werfel T. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy. J Dtsch Dermatol Ges 2009; 7: 739-42.
133. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis - an emerging concept. Allergy 2009; 64: 276-78.
134. Bokuniewicz M, Leung D, Bedford D. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010; 125: 4-13.
135. Pawiñska A. Bakteryjne zakażenia skóry i tkanek miȩkkich. Medycyna po Dyplomie Postȩpy 2009; 3: 45-50.
136. Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008; 68: 855-73.
137. Akhavan A, Rudikoff D. Atopic dermatitis: systemic immunosuppressive therapy. Semin Cutan Med Surg 2008; 27: 151-5.
138. Czarnecka-Operacz M. Immunoterapia swoista w leczeniu chorych na atopowe zapalenie skóry. Rozprawa habilitacyjna. Poznañ, 2000.
139. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007; 7: 542-6.
140. Czarnecka-Operacz M. Allergy vaccines in the treatment of atopic dermatitis. Int Rev Allergol Clin Immunol 2001; 7: 5-8.
141. Czarnecka-Operacz M. Total IgE and antigen specific IgE in patients with atopic dermatitis and airborne allergy treated with specific immunotherapy. Int Rev Allergol Clin Immunol 2001; 7: 16-26. (Pubitemid 32240004)
142. Czarnecka-Operacz M, Silny M, Sobieska M. Serum levels of IFN-γ, IL-2R, IL-4, IL-5 and IL-10 in the course of specific immunotherapy of patients with atopic dermatitis. Int Rev Allergol Clin Immunol 2001; 7: 27-33. (Pubitemid 32240005)
143. Czarnecka-Operacz M, Silny W. Analiza wpływu szczepionek alergenowych na przebieg atopowego zapalenia skóry u pacjentów z alergia̧ powietrznopochodna̧. Czȩść pierwsza - ocena kliniczna. Post Dermatol Alergol 2001; 18: 90-105.
144. Czarnecka-Operacz M, Silny W. Analiza wpływu szczepionek alergenowych na przebieg atopowego zapalenia skóry u pacjentów z alergia̧ powietrznopochodna̧. Czȩść druga - ocena kliniczna cia̧g dalszy. Post Dermatol Alergol 2001; 18: 221-35.
145. Czarnecka-Operacz M, Silny W. Analiza wpływu szczepionek alergenowych na przebiegatopowego zapalenia skóry u pacjentów z alergia̧ powietrznopochodna̧. Cze¸ść trzecia - ocena natychmiastowej reakcji skórnej w odniesieniu do wybranych alergenów środowiskowych. Post Dermatol Alergol 2002; 19: 26-37.
146. Silny W, Czarnecka-Operacz M, Silny P. Ocena skuteczności alergenowej immunoterapii swoistej w leczeniu atopowego zapalenia skóry u dzieci i młodzieży. Cze¸ść I. Ocena stanu klinicznego. Wiad Lek 2005; 58: 47-55.
147. Silny W, Czarnecka-Operacz M, Silny P. Ocena skuteczności alergenowej immunoterapii swoistej w leczeniu atopowego zapalenia skóry u dzieci i młodzieży. Cze¸ść II. Wyniki oceny reaktywności skóry i ste¸żenia antygenowo swoistych immunoglobulin klasy E w surowicy krwi w odniesieniu do wybranych alergenów powietrznopochodnych. Wiad Lek 2005; 58: 184-91.
148. Silny W, Czarnecka-Operacz M, Silny P. Ocena skuteczności alergenowej immunoterapii swoistej w leczeniu atopowego zapalenia skóry u dzieci i młodzieży. Cze¸ść III. Surowicze poziomy wybranych parametrów immunologicznych. Wiad Lek 2005; 58: 287-94.
149. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis. Results of a double-blind, placebo-controlled study. Allergologie 2006; 05: 171-83.
150. Lane JE, Cheyney PA, Lane TN. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-72.
151. Krathen R, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53: 338-40. (Pubitemid 40979597)
152. Grundmann-Kollmann M, Podda M, Ochsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137: 870-73.
153. Bremmer MS, Bremmer SF, Baig-Lewis S, et al. Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions. J Am Acad Dermatol 2009; 61: 666-76.
154. Wolska H. Fototerapia w dermatologii. Czelej, Lublin 2006; 142-50.